(Q46922861)

26 December 2017

review article

1 reference

title

The influence of drug-like concepts on decision-making in medicinal chemistry (English)

1 reference

26 December 2017

1 reference

Paul D Leeson

1

1 reference

26 December 2017

Brian Springthorpe

series ordinal

2

1 reference

26 December 2017

publication date

1 November 2007

1 reference

26 December 2017

Nature Reviews Drug Discovery

published in

1 reference

26 December 2017

volume

6

1 reference

26 December 2017

issue

11

1 reference

26 December 2017

page(s)

881-890

1 reference

26 December 2017

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

cites work

1 reference

Lead- and drug-like compounds: the rule-of-five revolution

31 March 2020

1 reference

Hydrogen bonding. 32. An analysis of water-octanol and water-alkane partitioning and the delta log P parameter of seiler.

31 March 2020

1 reference

A comparison of physiochemical property profiles of development and marketed oral drugs

31 March 2020

1 reference

Characteristic physical properties and structural fragments of marketed oral drugs.

31 March 2020

1 reference

The evolution of synthetic oral drug properties.

31 March 2020

1 reference

ADME evaluation in drug discovery. 7. Prediction of oral absorption by correlation and classification

31 March 2020

1 reference

Computational prediction of oral drug absorption based on absorption rate constants in humans

31 March 2020

1 reference

Molecular properties that influence the oral bioavailability of drug candidates

31 March 2020

1 reference

Influence of molecular flexibility and polar surface area metrics on oral bioavailability in the rat

31 March 2020

1 reference

31 March 2020

A bioavailability score.

1 reference

ADME evaluation in drug discovery. 6. Can oral bioavailability in humans be effectively predicted by simple molecular property-based rules?

31 March 2020

1 reference

The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds

31 March 2020

1 reference

Current trends in lead discovery: are we looking for the appropriate properties?

31 March 2020

1 reference

Dependence of molecular properties on proteomic family for marketed oral drugs

31 March 2020

1 reference

Global mapping of pharmacological space

31 March 2020

1 reference

31 March 2020

1 reference

Identification and evaluation of molecular properties related to preclinical optimization and clinical fate

31 March 2020

1 reference

Structure-based maximal affinity model predicts small-molecule druggability.

31 March 2020

1 reference

Druggability indices for protein targets derived from NMR-based screening data

31 March 2020

1 reference

Prospects for productivity

31 March 2020

1 reference

Property-based design: optimization of drug absorption and pharmacokinetics

31 March 2020

1 reference

The Role of Hydrophobicity in Toxicity Prediction

31 March 2020

1 reference

Analysis of drug-induced effect patterns to link structure and side effects of medicines

31 March 2020

1 reference

Can we rationally design promiscuous drugs?

31 March 2020

1 reference

The physicochemical challenges of designing multiple ligands

31 March 2020

1 reference

Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc

31 March 2020

1 reference

Modulators of the human CCR5 receptor. Part 3: SAR of substituted 1-[3-(4-methanesulfonylphenyl)-3-phenylpropyl]-piperidinyl phenylacetamides.

31 March 2020

1 reference

Potent 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists: effects of fused heterocycles on antiviral activity and pharmacokinetic properties

31 March 2020

1 reference

A quantitative assessment of hERG liability as a function of lipophilicity

31 March 2020

1 reference

Degradative transport of cationic amphiphilic drugs across phospholipid bilayers.

31 March 2020

1 reference

Fragment screening: an introduction

31 March 2020

1 reference

ADMET in silico modelling: towards prediction paradise?

31 March 2020

1 reference

Predicting oral absorption and bioavailability

31 March 2020

1 reference

In silico ADMET traffic lights as a tool for the prioritization of HTS hits

31 March 2020

1 reference

Improving the hit-to-lead process: data-driven assessment of drug-like and lead-like screening hits

31 March 2020

1 reference

Components of successful lead generation

31 March 2020

1 reference

Key aspects of the Novartis compound collection enhancement project for the compilation of a comprehensive chemogenomics drug discovery screening collection

31 March 2020

1 reference

On sampling of fragment space

31 March 2020

1 reference

Molecular complexity and its impact on the probability of finding leads for drug discovery

31 March 2020

1 reference

Is there a difference between leads and drugs? A historical perspective

31 March 2020

1 reference

A guide to drug discovery: The role of the medicinal chemist in drug discovery — then and now

31 March 2020

1 reference

Organic chemistry in drug discovery

31 March 2020

1 reference

Drug-like properties: guiding principles for design - or chemical prejudice?

31 March 2020

1 reference

Can the pharmaceutical industry reduce attrition rates?

31 March 2020

1 reference

Oral delivery of G protein-coupled receptor modulators: an explanation for the observed class difference

31 March 2020

1 reference

Modeling promiscuity based on in vitro safety pharmacology profiling data

31 March 2020

1 reference

Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRD2445

1 reference

26 December 2017

1 reference

26 December 2017